Collection from MedEngine

A regimen with caplacizumab, immunosuppression and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Coppo et al. Blood 2021; 137(6): 733–742.
This article was published on February 11, 2021, at ashpublications.org.
DOI: 10.1182/blood.2020008021

Select your desired language:

Extra: Additional Content

TTP: the evolution of clinical practice

Access ePrint

Blood Podcast: Season 2, Episode 6

Featuring a discussion of the Coppo trial
To access all episodes of the Blood Podcast, on a range of hematology topics, please click here
Content © 2021 by The American Society of Hematology
Site provided by Springer Healthcare. Part of the Springer Nature Group.
Privacy Policy